StriveWeekly: Self-Guided Online Intervention for Anxiety, Depression, and Stress in University Students

Sponsor
University of California, Los Angeles (Other)
Overall Status
Completed
CT.gov ID
NCT04361045
Collaborator
(none)
1,631
1
2
6.1
268.3

Study Details

Study Description

Brief Summary

This study was a randomized controlled trial of an original online mental health promotion program. This study aimed to: 1) establish program effectiveness by examining symptom change between conditions and 2) examine predictors of symptom change. The program was previously tested in open trial feasibility study by the same Principal Investigator and has since been rebuilt as informed by feasibility findings and participant qualitative feedback.

Participants were randomly assigned to either a waitlist condition or eight weeks of the intervention condition. Baseline, posttest, and follow-up electronic surveys collected self-reported symptoms of stress, anxiety, and depression. Motivational variables were also assessed at baseline and then tested as moderators of intervention effects.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: StriveWeekly
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1631 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Randomized Control Trial of Online Mental Health Promotion Program for University Students
Actual Study Start Date :
Sep 14, 2017
Actual Primary Completion Date :
Mar 18, 2018
Actual Study Completion Date :
Mar 18, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Condition

Participants in this condition were delivered 8 weeks of online intervention modules and then were invited to complete a posttest survey.

Behavioral: StriveWeekly
The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program "brand name" versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an "extras" section for tips/suggestions; and a weekly prize drawing. The "Dashboard" section of the intervention displayed user progress. The "Campus" section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity. Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning.
Other Names:
  • The Happiness Challenge
  • ReBoot Camp
  • No Intervention: Waitlist Condition

    Participants in this condition received no intervention content nor communications for 8 weeks and then were invited to complete a posttest survey.

    Outcome Measures

    Primary Outcome Measures

    1. Depression Anxiety and Stress Scale (DASS-21) [[Time Frame: Baseline to Posttest (~8 weeks)]]

      This 21-item self-report measure assesses symptoms of depression, anxiety, and stress. Individual items are rated 0 (Did not apply to me at all) to 3 (Applied to me very much or most of the time), with total scores ranging 0 - 63. Lower scores at posttest relative to baseline indicate improvement.

    Secondary Outcome Measures

    1. Program Adherence [[Time Frame: Baseline to Posttest (~8 weeks)]]

      This outcome was assessed based on number of modules with 1+ skills practice log. Skills practice logs were recorded as behavioral data, stored within the online platform's database of user account activity.

    2. Program Satisfaction [Posttest (~8 weeks)]

      This 5-item measure was adapted from the Client Satisfaction Questionnaire. Individual items are rated 1 (Poor) to 4 (Excellent), with total scores ranging 5 - 20. Higher scores indicate more satisfaction.

    Other Outcome Measures

    1. Subjective Happiness Scale [[Time Frame: Baseline to Posttest (~8 weeks)]]

      This 4-item self-report measure assesses subjective happiness. Individual items are rated 1 to 7, with total scores ranging 4 - 28. Higher scores at posttest relative to baseline indicate improvement.

    2. Patient Health Questionnaire-9 [[Time Frame: Baseline to Posttest (~8 weeks)]]

      This 9-item self-report measure assesses symptoms of major depressive disorder. Individual items are rated 0 (Not at all) to 3 (Nearly every day), with total scores ranging 0 - 27. Lower scores at posttest relative to baseline indicate improvement.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • enrolled as a student at UCLA (Fall 2017 - Winter 2018)
    Exclusion Criteria:
    • concurrent enrollment in a similar online anxiety and depression treatment study on campus

    • invalid data reporting (e.g., straight-lined responses to surveys) -- post hoc exclusion

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California, Los Angeles Los Angeles California United States 90095

    Sponsors and Collaborators

    • University of California, Los Angeles

    Investigators

    • Study Chair: Denise Chavira, PhD, University of California, Los Angeles
    • Principal Investigator: Leslie Leslie, PhD, Harvard University

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Leslie Rith-Najarian, PhD, Postdoctoral Fellow and Principal Investigator, Harvard University
    ClinicalTrials.gov Identifier:
    NCT04361045
    Other Study ID Numbers:
    • 17-000761
    First Posted:
    Apr 24, 2020
    Last Update Posted:
    Apr 24, 2020
    Last Verified:
    Apr 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 24, 2020